Otras publicaciones archivos - Página 7 de 8

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression

Erill N ¹, Colomer A ¹, Verdú M ², Román R ^1, Condom E ^2, Hannaoui N ^3, Banús JM ^3, Cordón-Cardó C ⁴, and Puig X ^1,2.

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; ³ICUN, Barcelona; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Altered p53 status is a frequent event in bladder cancer and reported to have prognostic significance. We studied the TP53gene and its product in 76 patients affected with urinary bladder carcinomas by immunohistochemistry (mAb DO-7), […]

Alberto 2004-02-09T22:14:36+00:00

Microsatellite analysis of chromosome 18 in colorectal cancer

Erill N¹, Colomer A¹, Calvo M³, Vidal A², Román R ¹, Verdú M², Cordon-Cardo C⁴, Puig X ^1,2.

¹BIOPAT, ²HISTOPAT Laboratoris, ³Statistics Dept. of the Universitat de Barcelona, Spain; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Chromosome 18q allelic loss (c18q LOH) seems to have prognostic significance in stage II colorectal carcinoma. In our laboratory c18q LOH was prospectively analyzed in a series of primary colorectal tumors using five markers (D18S55/58/61/64 and 69). Results of 207 PCR-based assays […]

Alberto 2003-07-23T17:00:47+00:00

Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas

Anna Colomer,¹ Nadina Erill,¹ Montse Verdú,² Ruth Roman,¹ August Vidal,^1,2 Carlos Cordon-Cardo,^1,3 Xavier Puig^1,2

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; and ³Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied a series of […]

Alberto 2003-07-23T16:51:27+00:00

HER-2/neu status in breast carcinoma: overexpression versus amplification

Verdú M^1,Colomer A^2,Román R^2,Erill N^2,Moreno A^1,Cordón-Cardo C^1,2,Puig X^1,2.

¹HISTOPAT Laboratoris & ²BIOPAT. Grup Assistència. Barcelona (Spain).

HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) to detect HER-2/neu protein overexpression was initially recommended as the technique of choice to assign patients to Herceptin clinical treatment. However, different studies have shown […]

Alberto 2003-02-23T17:27:24+00:00

Molecular evaluation of TP53 status in human colorectal and urinary bladder cancer: phenotype versus genotype analysis

Erill N¹, Colomer A¹, Verdú M², Román R¹, Vidal A², Condom E², Banús JM³, Cordón-Cardo C^1,2, Puig X^1,2.

¹BIOPAT. Grup Assistència, ²HISTOPAT Laboratoris & ³ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).

Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to define the TP53 status […]

Alberto 2003-02-23T16:49:37+00:00

Previous 5 6 7 8 Next